These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
254 related articles for article (PubMed ID: 35693456)
1. Selectivity and Maximum Response of Vibegron and Mirabegron for β Brucker BM; King J; Mudd PN; McHale K Curr Ther Res Clin Exp; 2022; 96():100674. PubMed ID: 35693456 [TBL] [Abstract][Full Text] [Related]
2. Vibegron shows high selectivity and potent agonist activity for β3-adrenoceptors, irrespective of receptor density. Yamamoto S; Kusabuka H; Matsuzawa A; Maruyama I; Yamazaki T PLoS One; 2023; 18(9):e0290685. PubMed ID: 37656760 [TBL] [Abstract][Full Text] [Related]
3. Efficacy of Vibegron and Mirabegron for Overactive Bladder: A Systematic Literature Review and Indirect Treatment Comparison. Kennelly MJ; Rhodes T; Girman CJ; Thomas E; Shortino D; Mudd PN Adv Ther; 2021 Nov; 38(11):5452-5464. PubMed ID: 34537953 [TBL] [Abstract][Full Text] [Related]
4. Comparative analysis of real-world adherence and persistence patterns with vibegron, mirabegron, and anticholinergics in patients with overactive bladder: A retrospective claims study. Chastek B; Carrera A; Landis C; Snyder D; Abedinzadeh L; Bancroft T; Nesheim J; Kennelly M; Staskin D Neurourol Urodyn; 2024 Sep; 43(7):1504-1513. PubMed ID: 38720543 [TBL] [Abstract][Full Text] [Related]
5. Long-term efficacy and safety of vibegron versus mirabegron and anticholinergics for overactive bladder: a systematic review and network meta-analysis. Kennelly M; Wielage R; Shortino D; Thomas E; Mudd PN Drugs Context; 2022; 11():. PubMed ID: 36303599 [TBL] [Abstract][Full Text] [Related]
6. Efficacy of vibegron, a novel β3-adrenoreceptor agonist, on severe urgency urinary incontinence related to overactive bladder: post hoc analysis of a randomized, placebo-controlled, double-blind, comparative phase 3 study. Yoshida M; Takeda M; Gotoh M; Yokoyama O; Kakizaki H; Takahashi S; Masumori N; Nagai S; Minemura K BJU Int; 2020 May; 125(5):709-717. PubMed ID: 31991511 [TBL] [Abstract][Full Text] [Related]
7. Clinical Utility of β Krhut J; Skugarevská B; Míka D; Lund L; Zvara P Res Rep Urol; 2022; 14():167-175. PubMed ID: 35502186 [TBL] [Abstract][Full Text] [Related]
8. Vibegron inhibits enhanced spontaneous contractions induced by anoxia/reoxygenation in isolated whole bladder from rats. Ikeda M; Nakada A; Abukawa H; Yamazaki T; Maruyama I Eur J Pharmacol; 2022 Jul; 926():175017. PubMed ID: 35588870 [TBL] [Abstract][Full Text] [Related]
10. Long-term safety and efficacy of the novel β Yoshida M; Kakizaki H; Takahashi S; Nagai S; Kurose T Int J Urol; 2018 Jul; 25(7):668-675. PubMed ID: 29752752 [TBL] [Abstract][Full Text] [Related]
11. Clinical pharmacology of β-3 adrenergic receptor agonists for cardiovascular diseases. Balligand JL; Michel LYM Expert Rev Clin Pharmacol; 2023; 16(11):1073-1084. PubMed ID: 37728503 [TBL] [Abstract][Full Text] [Related]
12. Selective activation of beta3-adrenoceptors by octopamine: comparative studies in mammalian fat cells. Carpéné C; Galitzky J; Fontana E; Atgié C; Lafontan M; Berlan M Naunyn Schmiedebergs Arch Pharmacol; 1999 Apr; 359(4):310-21. PubMed ID: 10344530 [TBL] [Abstract][Full Text] [Related]
13. Characterization of mexiletine as an antagonist of beta-adrenoceptor in Chinese hamster ovary cells expressing cloned human beta-adrenoceptors. Sakamoto K; Karikomi Y; Kubota Y; Nakahara T; Ishii K Biochem Pharmacol; 2004 Mar; 67(5):815-22. PubMed ID: 15104234 [TBL] [Abstract][Full Text] [Related]
16. The β Mo W; Michel MC; Lee XW; Kaumann AJ; Molenaar P Br J Pharmacol; 2017 Aug; 174(16):2706-2715. PubMed ID: 28574581 [TBL] [Abstract][Full Text] [Related]
17. Additive effects of intravenous and intravesical application of vibegron, a β Furuta A; Suzuki Y; Igarashi T; Koike Y; Kimura T; Egawa S; Yoshimura N Naunyn Schmiedebergs Arch Pharmacol; 2020 Nov; 393(11):2073-2080. PubMed ID: 32556396 [TBL] [Abstract][Full Text] [Related]
18. Pharmacological profile of the selective β3-adrenoceptor agonist mirabegron in cynomolgus monkeys. Hatanaka T; Ukai M; Watanabe M; Someya A; Ohtake A; Suzuki M; Ueshima K; Sato S; Masuda N Naunyn Schmiedebergs Arch Pharmacol; 2013 Nov; 386(11):1001-8. PubMed ID: 23832377 [TBL] [Abstract][Full Text] [Related]
19. Vibegron, a Novel Potent and Selective β Yoshida M; Takeda M; Gotoh M; Nagai S; Kurose T Eur Urol; 2018 May; 73(5):783-790. PubMed ID: 29366513 [TBL] [Abstract][Full Text] [Related]
20. Efficacy of vibegron in patients with overactive bladder: Multicenter prospective study of real-world clinical practice in Japan, SCCOP study 19-01. Tachikawa K; Kyoda Y; Fukuta F; Kobayashi K; Masumori N Low Urin Tract Symptoms; 2022 Mar; 14(2):109-116. PubMed ID: 34713579 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]